This 2 arm study will assess the efficacy and safety of intravenous Bonviva in patients with osteoporosis experiencing pain after recent vertebral osteoporotic fracture. Patients will be randomized to receive either Bonviva (3mg i.v. bolus injection) or placebo. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

Inclusion Criteria:

• postmenopausal women or men >30 years of age;
• osteoporosis;
• vertebral osteoporotic fracture in past 4 weeks;
• fracture-related pain requiring analgesic treatment.

Exclusion Criteria:

• non-menopausal women;
• current treatment with another bisphosphonate;
• current treatment with class III analgesics.